Correlation Between Aion Therapeutic and Amexdrug
Can any of the company-specific risk be diversified away by investing in both Aion Therapeutic and Amexdrug at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aion Therapeutic and Amexdrug into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aion Therapeutic and Amexdrug, you can compare the effects of market volatilities on Aion Therapeutic and Amexdrug and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aion Therapeutic with a short position of Amexdrug. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aion Therapeutic and Amexdrug.
Diversification Opportunities for Aion Therapeutic and Amexdrug
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Aion and Amexdrug is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Aion Therapeutic and Amexdrug in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Amexdrug and Aion Therapeutic is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aion Therapeutic are associated (or correlated) with Amexdrug. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Amexdrug has no effect on the direction of Aion Therapeutic i.e., Aion Therapeutic and Amexdrug go up and down completely randomly.
Pair Corralation between Aion Therapeutic and Amexdrug
If you would invest 1.54 in Aion Therapeutic on December 28, 2024 and sell it today you would lose (0.99) from holding Aion Therapeutic or give up 64.29% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 96.83% |
Values | Daily Returns |
Aion Therapeutic vs. Amexdrug
Performance |
Timeline |
Aion Therapeutic |
Amexdrug |
Aion Therapeutic and Amexdrug Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Aion Therapeutic and Amexdrug
The main advantage of trading using opposite Aion Therapeutic and Amexdrug positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aion Therapeutic position performs unexpectedly, Amexdrug can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amexdrug will offset losses from the drop in Amexdrug's long position.Aion Therapeutic vs. Amexdrug | Aion Therapeutic vs. The BC Bud | Aion Therapeutic vs. Crescita Therapeutics |
Amexdrug vs. Zai Lab | Amexdrug vs. C4 Therapeutics | Amexdrug vs. Erasca Inc | Amexdrug vs. Cullinan Oncology LLC |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Complementary Tools
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |